|
Malignant neoplasm of prostate
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Our data reveal the endogenous need of prostate cancer cells for modified KLK5 expression to cope with the administration of chemotherapeutic drugs.
|
20128692 |
2010 |
|
Malignant neoplasm of prostate
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
ROC analysis demonstrated that KLK5 expression had significant discriminatory value between BPH and PCa (AUC 0.64; P = 0.016).
|
19299547 |
2009 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
CTD_human |
Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression.
|
16517595 |
2006 |
|
Malignant neoplasm of prostate
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
KLK5 has been shown to be differentially expressed in a variety of endocrine tumors including ovarian, breast and prostate cancer.
|
15627884 |
2005 |
|
Malignant neoplasm of prostate
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
KLK5-SV1 is expressed at high levels in ovarian, pancreatic, breast and prostate cancer cell lines.
|
15361712 |
2004 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
BEFREE |
KLK5 should be further studied as a potential new prognostic marker in prostate cancer, whose expression is negatively correlated with cancer aggressiveness.
|
11948967 |
2002 |
|
Prostatic Neoplasms
|
0.330 |
GeneticVariation
|
group |
LHGDN |
Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.
|
19190824 |
2009 |
|
Prostatic Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression.
|
16517595 |
2006 |
|
Prostatic Neoplasms
|
0.330 |
Biomarker
|
group |
LHGDN |
Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression.
|
16517595 |
2006 |
|
Prostatic Neoplasms
|
0.330 |
AlteredExpression
|
group |
LHGDN |
Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
|
11948967 |
2002 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we use transcriptional profiling experiments to show that PRSS3/mesotrypsin and KLK5 control a common malignancy-promoting pathway.
|
30755669 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Association of KLK5 mRNA expression with PFS was validated in silico using The Cancer Genome Atlas.
|
31307411 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Receiver operating characteristic (ROC) analysis demonstrated for first time that KLK5 expression had significant discriminatory values between cancer and adenoma tissues (area under the curve [AUC] 0.77; 95% confidence interval [CI]=0.69-0.85, p=0.03).
|
30759066 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mRNA levels were correlated with KLK5 antigen tumor tissue levels measured by ELISA (available for 41 of the 138 patients), established clinical features as well as patients' outcome, using Chi-square-tests, Mann-Whitney U-tests and Spearman rank calculations as well as Cox regression models, Kaplan-Meier survival analysis and the log-rank test.
|
31307411 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Kallikrein-related peptidases KLK5, KLK7 and KLK14 are important proteases in skin desquamation and aberrant KLK activity is associated with inflammatory skin diseases such as Netherton syndrome but also with various serious forms of cancer.
|
29494334 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This explains the higher tumor numbers observed in Klk5-/- compared to wildtype.
|
29561728 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The KLK5 mRNA expression levels were significantly upregulated in CRC tissues compared with the paired normal tissues, and were higher in Dukes' stage C/D cancer than in stage A/B (P<0.001).
|
27430713 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, increased serum KLK5 levels were associated with CRC lymph node or distant metastasis (P=0.003), tumor‑lymph node‑metastasis stage (P=0.004), and Dukes' stage (P=0.005).
|
27430713 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we show that reconstitution of KLK5 expression in non-expressing MDA-MB-231 breast cancer cells suppresses malignancy in vitro and in vivo dose-dependently.
|
24158494 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have previously shown that four kallikrein-related (KLK) peptidases, KLK4, KLK5, KLK6 and KLK7 (KLK4-7), are implicated in peritoneal invasion and tumour growth, but underlying mechanisms were not identified.
|
22964375 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have previously reported that expression of a panel of serine proteinase kallikreins (KLK 5, 7, 8, and 10) is correlated with formation of more aggressive OSCC tumors in a murine orthotopic OSCC model and is elevated in human OSCC.
|
21163944 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A trend for upregulation in tumors was observed for (CANFA)KLK5, (CANFA)KLK7, and (CANFA)KLK8, whereas (CANFA)KLK8 variant 1 tended to be downregulated in cancer.
|
20853168 |
2010 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mRNA levels of KLK5 and KLK7 were positively correlated in breast malignancies.
|
19453546 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reverse transcription-polymerase chain reaction analysis of 42 primary bladder tumor samples showed that increased expression of KLK5 was frequently observed in invasive tumors (pT2-pT4) (14.3%, 6/42) compared with superficial tumors (pTa, pT1) (0%, 0/42; P = 0.0052), and expression levels of KLK5, -6, -8 and -9 mRNA were higher in invasive tumors than in superficial tumors (P < 0.0001, P = 0.0043, P = 0.0790 and P = 0.0037, respectively).
|
17459052 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
KLK5 has been shown to be differentially expressed in a variety of endocrine tumors including ovarian, breast and prostate cancer.
|
15627884 |
2005 |